In this exclusive PC Podcast interview, Mark Bouck, chairman and CEO of PharmAlliance, a pharmaceutical and life sciences services platform, dives into: How PharmAlliance’s acquisition of Complete Health Economics Outcomes Research Solutions (CHEORS) helps expand global reach The platform’s biggest goal to when it comes to CHEORS and market access…
-
-
Image Credit: Adobe Stock Images/MPStudio.com Abzena, a contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, and Argonaut Manufacturing Services, Inc., a current good manufacturing practice (cGMP) CDMO that operates in the diagnostics and biopharmaceutical and diagnostics sectors, have decided to partner up to design a fully integrated…
-
Image Credit: Adobe Stock Images/iKatod.com As part of the company’s commercial plan, Bora Pharmaceuticals Co., Ltd., a contract development and manufacturing organization (CDMO), will be acquiring Emergent BioSolutions’ 87,000 square-foot sterile manufacturing facility in Baltimore-Camden, MD.1 The current site’s staff will also have the option to join the Bora team…
-
Image Credit: Adobe Stock Images/IFoto.com Racial inequalities—and their impact on health outcomes—can be influenced by treatment differences due to a change in clinical practices according to location, implicit bias, limited access to care, social determinants of health, and systemic and historical racism. Over the years, there has been a larger…
-
In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses what to expect from Cardinal Health’s biosimilars pipeline.
-
Sustainability has become a primary focus for many pharmaceutical manufacturers and suppliers, but there is more to sustainability than employing multi-use supplies and materials. To learn more, Pharmaceutical Commerce sat down with Kevin Lynch, Vice President of Global Sales at QProducts & Services, to learn more about the company’s initiatives…
-
Ensuring Ethical Practices in Light of Potential Misuse In this part of his Pharmaceutical Executive video interview, Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, talks about what steps companies developing weight-loss medications should take to ensure responsible and ethical practices. Drug Shortages in Community Oncology: Ensuring Access…
-
PC: You had previously penned a byline for Pharma Commerce in which you described how the biosimilars market has experienced massive growth, but regulatory and adoption challenges remain. Could you elaborate further on that? Gregory: Things are moving very quickly in the biosimilars world as they always have been. I…
-
Improving Quality of Care for Cancer Patients In fourth and final part of this video interview, Marc Buyse, founder, and Sebastien Coppe, CEO; both of One2Treat emphasize the importance of personalizing oncology studies and giving patients more choices. Why We Can’t Give Up on Value-Based Care | AHIP 2024 Scott…
-
Wacker Biotech, a therapeutic protein contract manufacturer, recently opened up an mRNA competence center at its biotech site in Halle (Saale), Germany.1 The new facility—which broke ground in 20222 and was funded for $107 million—has the capability to handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid (mRNA),…